Andere Sprachen FibroGen, Inc.

Aktien

A12EZ0

US31572Q8087

FGEN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
1,2 ^USD	-3,23 %		+3,45 %	+35,39 %

07.05.	Top-Zuwächse vorbörslich	MT
06.05.	Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS	08.05.
FibroGen : Corporate Presentation – May 2024	08.05.
Top Premarket Gainers	07.05.
FibroGen to Participate in Upcoming Investor Conferences	07.05.
FibroGen: Q1 Earnings Snapshot	06.05.
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M	06.05.
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
FibroGen Reports First Quarter 2024 Financial Results	06.05.
FibroGen to Report First Quarter 2024 Financial Results	29.04.
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	24.04.
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	24.04.
Faron Pharmaceuticals reappoints former finance chief on interim basis	15.04.
Top Midday Decliners	03.04.
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	03.04.
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02.04.
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02.04.
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	26.03.
FibroGen : Corporate Presentation – March 2024	19.03.
Sector Update: Health Care Stocks Rise Late Afternoon	12.03.
Sector Update: Health Care Stocks Higher in Afternoon Trading	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen FibroGen, Inc.

Aktien

A12EZ0

US31572Q8087

FGEN

Andere Sprachen

Filter